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1. INTRODUCTION {#joa312154-sec-0005}
===============

Atrial fibrillation (AF) occurs in 6%‐21% of patients with acute coronary syndrome (ACS).[1](#joa312154-bib-0001){ref-type="ref"}, [2](#joa312154-bib-0002){ref-type="ref"}, [3](#joa312154-bib-0003){ref-type="ref"}, [4](#joa312154-bib-0004){ref-type="ref"}, [5](#joa312154-bib-0005){ref-type="ref"}, [6](#joa312154-bib-0006){ref-type="ref"}, [7](#joa312154-bib-0007){ref-type="ref"}, [8](#joa312154-bib-0008){ref-type="ref"}, [9](#joa312154-bib-0009){ref-type="ref"}, [10](#joa312154-bib-0010){ref-type="ref"}, [11](#joa312154-bib-0011){ref-type="ref"}, [12](#joa312154-bib-0012){ref-type="ref"}, [13](#joa312154-bib-0013){ref-type="ref"}, [14](#joa312154-bib-0014){ref-type="ref"}, [15](#joa312154-bib-0015){ref-type="ref"} AF causes loss of "atrial kick," tachycardia and irregular rhythm because it decreases cardiac output.[16](#joa312154-bib-0016){ref-type="ref"}, [17](#joa312154-bib-0017){ref-type="ref"} Therefore, it has been considered that ACS patients with AF have a worse prognosis than patients without AF. Several studies have identified increased mortality attributed to complication of ACS with AF.[1](#joa312154-bib-0001){ref-type="ref"}, [2](#joa312154-bib-0002){ref-type="ref"}, [3](#joa312154-bib-0003){ref-type="ref"}, [4](#joa312154-bib-0004){ref-type="ref"}, [5](#joa312154-bib-0005){ref-type="ref"}, [7](#joa312154-bib-0007){ref-type="ref"}, [8](#joa312154-bib-0008){ref-type="ref"}, [9](#joa312154-bib-0009){ref-type="ref"}, [11](#joa312154-bib-0011){ref-type="ref"}, [12](#joa312154-bib-0012){ref-type="ref"}, [13](#joa312154-bib-0013){ref-type="ref"}, [14](#joa312154-bib-0014){ref-type="ref"}, [15](#joa312154-bib-0015){ref-type="ref"}, [18](#joa312154-bib-0018){ref-type="ref"}, [19](#joa312154-bib-0019){ref-type="ref"}, [20](#joa312154-bib-0020){ref-type="ref"}, [21](#joa312154-bib-0021){ref-type="ref"}, [22](#joa312154-bib-0022){ref-type="ref"}, [23](#joa312154-bib-0023){ref-type="ref"}, [24](#joa312154-bib-0024){ref-type="ref"}, [25](#joa312154-bib-0025){ref-type="ref"}, [26](#joa312154-bib-0026){ref-type="ref"}, [27](#joa312154-bib-0027){ref-type="ref"} However, there is controversy as to whether AF is an independent predictor.[4](#joa312154-bib-0004){ref-type="ref"}, [14](#joa312154-bib-0014){ref-type="ref"}, [22](#joa312154-bib-0022){ref-type="ref"}, [27](#joa312154-bib-0027){ref-type="ref"}

Thus, it is thought that clinical factors other than AF may determine prognosis. In a number of studies, ACS patients with AF tend to be older than those without AF. There are also reports that such patients have a poor outcome after adjustment for patient clinical characteristics.[3](#joa312154-bib-0003){ref-type="ref"}, [8](#joa312154-bib-0008){ref-type="ref"}, [9](#joa312154-bib-0009){ref-type="ref"}, [11](#joa312154-bib-0011){ref-type="ref"}, [19](#joa312154-bib-0019){ref-type="ref"}, [20](#joa312154-bib-0020){ref-type="ref"}, [21](#joa312154-bib-0021){ref-type="ref"}, [24](#joa312154-bib-0024){ref-type="ref"} However, the evidence derived from these studies is quite limited.

Percutaneous coronary intervention (PCI) has become the first line treatment in ACS patients. However, while there have been many reports concerning AF in patients with ACS in the thrombolytic era,[1](#joa312154-bib-0001){ref-type="ref"}, [3](#joa312154-bib-0003){ref-type="ref"}, [5](#joa312154-bib-0005){ref-type="ref"}, [6](#joa312154-bib-0006){ref-type="ref"}, [18](#joa312154-bib-0018){ref-type="ref"}, [19](#joa312154-bib-0019){ref-type="ref"}, [20](#joa312154-bib-0020){ref-type="ref"}, [21](#joa312154-bib-0021){ref-type="ref"}, [23](#joa312154-bib-0023){ref-type="ref"} there still a small number of such reports in the PCI era.[4](#joa312154-bib-0004){ref-type="ref"}, [14](#joa312154-bib-0014){ref-type="ref"}, [22](#joa312154-bib-0022){ref-type="ref"}, [24](#joa312154-bib-0024){ref-type="ref"}, [27](#joa312154-bib-0027){ref-type="ref"}

Previous reports have suggested that mortality differed in patients with pre‐existing AF or new‐onset AF. Some reports directly compared each type of AF,[2](#joa312154-bib-0002){ref-type="ref"}, [5](#joa312154-bib-0005){ref-type="ref"}, [6](#joa312154-bib-0006){ref-type="ref"}, [8](#joa312154-bib-0008){ref-type="ref"}, [11](#joa312154-bib-0011){ref-type="ref"}, [12](#joa312154-bib-0012){ref-type="ref"}, [13](#joa312154-bib-0013){ref-type="ref"}, [14](#joa312154-bib-0014){ref-type="ref"}, [15](#joa312154-bib-0015){ref-type="ref"}, [23](#joa312154-bib-0023){ref-type="ref"}, [25](#joa312154-bib-0025){ref-type="ref"} and in some of the studies there were indications that new‐onset AF worsened the prognosis[2](#joa312154-bib-0002){ref-type="ref"}, [5](#joa312154-bib-0005){ref-type="ref"}, [8](#joa312154-bib-0008){ref-type="ref"}, [11](#joa312154-bib-0011){ref-type="ref"}, [12](#joa312154-bib-0012){ref-type="ref"}, [14](#joa312154-bib-0014){ref-type="ref"}, [15](#joa312154-bib-0015){ref-type="ref"}, [23](#joa312154-bib-0023){ref-type="ref"}; however, others concluded that new‐onset AF did not worsen the prognosis.[6](#joa312154-bib-0006){ref-type="ref"}, [13](#joa312154-bib-0013){ref-type="ref"}, [25](#joa312154-bib-0025){ref-type="ref"}

The aim of this study was to evaluate the prognostic value of AF as a complicating factor in patients with ACS, in the current PCI era; comparisons were made among non‐AF and all‐AF groups, and between non‐AF, new‐onset AF, and pre‐existing AF groups.

2. METHODS {#joa312154-sec-0006}
==========

This study retrospectively included 648 consecutive ACS patients admitted to our institute between December 2008 and December 2012. ACS was defined in accordance with the Third Universal Definition of Myocardial Infarction,[28](#joa312154-bib-0028){ref-type="ref"} incorporating ST‐elevated myocardial infarction (STEMI) and non‐ST‐elevated myocardial infarction (NSTEMI).

This was a retrospective cohort study. Demographics, past medical histories, clinical data, treatment, and major adverse cardiovascular events during in‐hospital and follow‐up periods, were collected. Coronary angiographic findings were evaluated according to the American Heart Association (AHA) classification.[29](#joa312154-bib-0029){ref-type="ref"} Significant coronary stenosis was defined as ≥75% stenosis of coronary artery by visual estimation. Significant stenosis of left main trunk (LM) was defined as ≥50% occlusion.

Primary end points were defined as all‐cause and cardiac deaths. Secondary end points were defined as recurrent myocardial infarction, bleeding event of more than grade three according to the BARC classification,[30](#joa312154-bib-0030){ref-type="ref"} cerebral infarction (CI)/transient ischemic cerebral attack (TIA), and congestive heart failure (CHF) requiring hospitalization. Clinical events were investigated from medical records. Time to outcome event was measured in months from the day of admission.

Patients with AF were divided into two groups: the new‐onset and the pre‐existing AF groups. New‐onset AF was defined as no past history of AF before admission and was observed for the first time during in‐hospital stays. Pre‐existing AF was defined as previously documented AF before admission, whether paroxysmal or persistent AF. While existence of valvular AF was an exclusion criterion, no such patients were identified during the study period.

Patients were first divided into AF‐absent (non‐AF) and AF‐present (all‐AF) groups. Second, study patients were further divided into three groups: non‐AF, new‐onset AF, and pre‐existing AF groups. We compared prognosis among these groups using Cox regression analysis.

2.1. Statistical analysis {#joa312154-sec-0007}
-------------------------

Data are presented as the mean ± SD. Comparison of means was performed using unpaired Student\'s *t* test and the Mann‐Whitney *U* test. Statistical differences in categorical data were explored using the chi‐squared test. Survival rates were assessed using the Kaplan‐Meier method. The cox proportional hazards regression analysis was used to identify clinical predictors for outcome events. Multivariate logistic regression analysis of significant clinical factors was carried out to identify determinants of prognosis. Factors such as CHADS~2~ score and emergency PCI or CABG related to multicollinearity were excluded from the analysis. *P*‐values less than 0.05 were considered significant. All analyses were performed using SPSS ver. 21.0 statistical software (Chicago, IL, USA).

3. RESULTS {#joa312154-sec-0008}
==========

The mean follow‐up period was 1.4 ± 1.2 years and the follow‐up rate of this study was 95%. Numbers of non‐AF and all‐AF patients were 538 and 110, respectively. Numbers of new‐onset AF and pre‐existing AF patients were 67 and 43, respectively. Patient clinical characteristics are shown in Table [1](#joa312154-tbl-0001){ref-type="table"}, and patients were divided into non‐AF and all‐AF groups. The all‐AF group was older and the prevalence of renal dysfunction, history of CI/TIA, peripheral artery disease (PAD), Killip classification ≥2, LM lesion, and CABG procedures was significantly higher than in the non‐AF group. There was no significant difference in in‐hospital mortality rates between the two groups.

###### 

Baseline clinical characteristics of non‐AF and all‐AF groups

                                                          Non‐AF group (n = 538)   All‐AF group (n = 110)   *P*
  ------------------------------------------------------- ------------------------ ------------------------ ---------
  Age, years ± SD                                         66.6 ± 12.5              74.0 ± 9.5               \<0.001
  Male, n (%)                                             420 (78.1)               85 (77.3)                0.855
  BMI, kg/m^2^ ± SD                                       24.3 ± 4.0               23.8 ± 3.3               0.233
  Hypertension, n (%)                                     371 (69.0)               85 (77.3)                0.082
  Dyslipidemia, n (%)                                     321 (59.7)               52 (47.2)                0.017
  Diabetes mellitus, n (%)                                197 (36.6)               46 (41.8)                0.305
  Renal dysfunction (eGFR \<60 mL/min/1.73 m^2^), n (%)   163 (30.3)               51 (46.4)                0.001
  Current smoker, n (%)                                   221 (41.1)               20 (18.2)                \<0.001
  Previous cerebral infarction or TIA, n (%)              53 (9.9)                 22 (20.0)                0.003
  Previous myocardial infarction, n (%)                   56 (10.4)                13 (11.8)                0.690
  Previous peripheral artery disease, n (%)               17 (3.2)                 10 (9.1)                 0.005
  STEMI, n (%)                                            381 (70.8)               68 (61.8)                0.062
  Killip\'s classification ≥2, n (%)                      143 (26.6)               56 (50.9)                \<0.001
  Left ventricular ejection fraction, % (SD)              49.8 (11.0)              47.6 (10.8)              0.053
  Multiple vessel disease, n (%)                          318 (59.1)               67 (60.9)                0.398
  Left main trunk lesion ≥50%, n (%)                      45 (8.4)                 18 (16.4)                0.006
  Emergency PCI, n (%)                                    436 (81.0)               75 (68.2)                0.001
  CABG, n (%)                                             17 (3.2)                 14 (12.7)                \<0.001
  Emergency PCI or CABG, n (%)                            449 (83.5)               89 (80.9)                0.517
  In‐hospital mortality, n (%)                            35 (6.5)                 12 (10.9)                0.105

BMI, body mass index; CABG, coronary artery bypass grafting; GFR, glomerular filtration rate; PCI, Percutaneous coronary intervention; STEMI, ST elevation myocardial infarction; TIA, transient ischemic attacks.

John Wiley & Sons, Ltd

3.1. Comparison among the non‐AF, new‐onset AF, and pre‐existing AF groups {#joa312154-sec-0009}
--------------------------------------------------------------------------

Patient clinical characteristics are shown in Table [2](#joa312154-tbl-0002){ref-type="table"} in which patients were divided into three groups: non‐AF, new‐onset AF, and pre‐existing AF groups. There was no significant difference in age between new‐onset and pre‐existing AF groups. Prevalence of a previous CI/TIA, PAD, and LM lesion was highest in patients with pre‐existing AF, but Killip classification ≥2 and CABG procedures were highest in patients with new‐onset AF. In addition, LVEF was lowest in the new‐onset AF group.

###### 

Baseline clinical characteristics of non‐AF, new‐onset AF, and pre‐existing AF groups

                                                          Non‐AF group (n = 538)   New‐onset AF group (n = 67)   Pre‐existing AF group (n = 43)   *P*
  ------------------------------------------------------- ------------------------ ----------------------------- -------------------------------- ---------
  Age, years ± SD                                         66.6 ± 12.5              73.0 ± 9.7                    75.5 ± 9.2                       \<0.001
  Male, n (%)                                             420 (78.1)               49 (73.1)                     36 (83.7)                        0.419
  BMI, kg/m^2^ ± SD                                       24.3 ± 4.0               24.1 ± 3.0                    23.5 ± 3.7                       0.346
  Hypertension, n (%)                                     371 (69.0)               50 (81.4)                     35 (81.4)                        0.165
  Dyslipidemia, n (%)                                     321 (59.7)               32 (47.8)                     20 (46.5)                        0.056
  Diabetes mellitus, n (%)                                197 (36.6)               28 (41.8)                     18 (41.9)                        0.590
  Renal dysfunction (eGFR \<60 mL/min/1.73 m^2^), n (%)   163 (30.3)               31 (46.3)                     20 (46.5)                        0.005
  Current smoker, n (%)                                   221 (41.1)               15 (22.4)                     5 (11.6)                         \<0.001
  Previous cerebral infarction or TIA, n (%)              53 (9.9)                 8 (11.9)                      14 (32.6)                        \<0.001
  Previous myocardial infarction, n (%)                   56 (10.4)                9 (13.4)                      4 (9.3)                          0.732
  Previous peripheral artery disease, n (%)               17 (3.2)                 4 (6.0)                       6 (14.0)                         0.002
  STEMI, n (%)                                            381 (70.8)               42 (62.7)                     26 (60.5)                        0.171
  Killip\'s classification ≥2, n (%)                      143 (26.6)               40 (59.7)                     16 (37.2)                        \<0.001
  Left ventricular ejection fraction, % (SD)              49.8 (11.0)              45.7 (11.0)                   50.4 (10.5)                      0.013
  Multiple vessel disease, n (%)                          318 (59.1)               41 (61.2)                     26 (60.5)                        0.697
  Left main trunk lesion ≥50%, n (%)                      45 (8.4)                 10 (14.9)                     8 (18.6)                         0.018
  Emergency PCI, n (%)                                    436 (81.0)               42 (62.7)                     33 (76.7)                        0.001
  CABG, n (%)                                             17 (3.2)                 11 (16.4)                     3 (7.0)                          \<0.001
  Emergency PCI or CABG, n (%)                            449 (83.5)               52 (77.6)                     37 (86.0)                        0.418
  CHADS~2~ score (SD)                                     ‐                        2.6 (1.5)                     3.2 (1.5)                        0.028
  In‐hospital mortality, n (%)                            35 (6.5)                 9 (13.4)                      3 (7.0)                          0.119

BMI, body mass index; CABG, coronary artery bypass grafting; GFR, glomerular filtration rate; PCI, Percutaneous coronary intervention; STEMI, ST elevation myocardial infarction; TIA, transient ischemic attacks.

John Wiley & Sons, Ltd

In‐hospital mortality rates tended to be higher in the new‐onset AF group than in the other groups, but the difference was not significant. CHADS~2~ score in the pre‐existing AF group was significantly higher than in the new‐onset AF group (CHADS~2~ score in the pre‐existing AF group was 3.2 ± 1.5, and CHADS~2~ score in the new‐onset AF group was 2.6 ± 1.5, *P* = 0.028, Table [2](#joa312154-tbl-0002){ref-type="table"}). Distribution of CHADS~2~ scores among patients is shown in Figure [1](#joa312154-fig-0001){ref-type="fig"}. Distribution of CHADS~2~ scores was significantly higher in the pre‐existing AF group than in the new‐onset AF group (*P* = 0.022).

![Distribution of CHADS ~2~ scores among the new‐onset AF and pre‐existing AF groups. The new‐onset AF group (blue bar) and pre‐existing AF group (orange bar). Distribution of CHADS ~2~ scores was significantly higher in the pre‐existing AF group than in the new‐onset AF group (*P* = 0.022)](JOA3-35-182-g001){#joa312154-fig-0001}

During the follow‐up period, 78 all‐cause deaths and 42 cardiac deaths were confirmed (Table [3](#joa312154-tbl-0003){ref-type="table"}).

###### 

Primary and secondary end points during follow‐up period

                                            Non‐AF group (n = 538)   New‐onset AF group (n = 67)   Pre‐existing AF group (n = 43)   Total (n = 648)
  ----------------------------------------- ------------------------ ----------------------------- -------------------------------- -----------------
  Primary end point                                                                                                                 
  All‐cause death, n (%)                    57 (10.6)                15 (22.4)                     6 (14.0)                         78 (12.0)
  Cardiac death, n (%)                      29 (5.4)                 10 (14.9)                     3 (7.0)                          42 (6.5)
  Secondary end point                                                                                                               
  Myocardial infarction recurrence, n (%)   11 (2.0)                 3 (4.4)                       0 (0)                            14 (2.2)
  Cerebral infarction/TIA, n (%)            9 (1.7)                  2 (3.0)                       3 (7.1)                          14 (2.2)
  Hemorrhage, n (%)                         47 (8.7)                 12 (17.9)                     4 (9.3)                          63 (9.7)
  Hospitalization on heart failure, n (%)   12 (2.2)                 5 (7.5)                       4 (9.3)                          21 (3.2)

Follow‐up periods; non‐AF group 1.3 ± 1.1 year, new‐onset AF group 1.5 ± 1.4 year, pre‐existing AF group 1.4 ± 1.2 year, *P* = 0.648.

Hemorrhage: BARC (Bleeding Academic Research Consortium) ≥3.

TIA, transient ischemic attacks.

John Wiley & Sons, Ltd

3.2. Long‐term prognostic differences when comparing two groups or three groups {#joa312154-sec-0010}
-------------------------------------------------------------------------------

In a comparison between the non‐AF and all‐AF groups, all‐AF patients had a worse prognosis than the non‐AF patients (Log‐Rank: *P* = 0.02) (Figure [2](#joa312154-fig-0002){ref-type="fig"}, left). When patients were divided into three groups, the new‐onset AF had a worse prognosis than the other groups (Log‐Rank: *P* = 0.025), as illustrated by the Kaplan‐Meier curves shown in Figure [2](#joa312154-fig-0002){ref-type="fig"}, right. However, long‐term mortality was not significantly different on the Cox proportional hazards regression analysis adjusted by age, sex, hypertension, hyperlipidemia, diabetes mellitus, current smoking, and renal dysfunction (Table [4](#joa312154-tbl-0004){ref-type="table"}). The hazard ratio of congestive heart failure requiring hospitalization was significantly higher in the all‐AF and new‐onset AF groups than in the non‐AF group. However, there was no significant difference in the pre‐existing AF group compared to the non‐AF group. Prevalence of hemorrhage, CI/TIA, or recurrent myocardial infarction showed no significant differences among the three groups.

![Kaplan‐Meier analysis of cumulative survival rates for patients with ACS during follow‐up period](JOA3-35-182-g002){#joa312154-fig-0002}

###### 

Cox‐regression analysis

                                     Non‐AF group vs All‐AF group   Non‐AF group vs New‐onset AF group   Non‐AF group vs Pre‐existing AF group                                  
  ---------------------------------- ------------------------------ ------------------------------------ --------------------------------------- ------- ---------------------- -------
  Primary end point                                                                                                                                                             
  All‐cause death                    1.032 (0.605‐1.761)            0.908                                1.341 (0.742‐2.422)                     0.331   0.636 (0.265‐1.526)    0.310
  Cardiac death                      1.112 (0.544‐2.272)            0.772                                1.461 (0.679‐3.142)                     0.332   0.597 (0.172‐2.067)    0.415
  Secondary end point                                                                                                                                                           
  Myocardial infarction recurrence   1.514 (0.391‐5.865)            0.548                                2.460 (0.648‐9.336)                     0.186   0 (0)                  0.986
  Cerebral infarction/TIA            1.594 (0.515‐4.938)            0.419                                1.030 (0.216‐4.921)                     0.970   2.573 (0.643‐10.299)   0.182
  Hemorrhage                         1.460 (0.806‐2.646)            0.212                                1.894 (0.990‐3.622)                     0.054   0.835 (0.292‐2.390)    0.737
  Hospitalization on heart failure   3.352 (1.323‐8.492)            0.011                                3.801 (1.301‐11.103)                    0.015   2.825 (0.812‐9.830)    0.103

Adjusted by age, sex, hypertension, dyslipidemia, diabetic mellitus, current smoker, renal dysfunction.

TIA, transient ischemic attacks.

John Wiley & Sons, Ltd

Because there were significant differences in age among these groups, we carried out additional Cox proportional hazards regression analysis in cases ≥75 or \<75 years of age. There was no significant difference in long‐term mortality between the two groups (Table [5](#joa312154-tbl-0005){ref-type="table"}). In multivariate logistic regression analysis, AF was not an independent predictor of all‐cause death. Significant independent predictors of all‐cause death were renal dysfunction, history of PAD, Killip classification ≥2, and LVEF (Table [6](#joa312154-tbl-0006){ref-type="table"}).

###### 

Cox‐regression analysis in cases ≥75 or \<75 years old

                      Non‐AF group vs All‐AF group   Non‐AF group vs New‐onset AF group   Non‐AF group vs Pre‐existing AF group                                 
  ------------------- ------------------------------ ------------------------------------ --------------------------------------- ------- --------------------- -------
  *≥75 years old*                                                                                                                                               
  Primary end point                                                                                                                                             
  All‐cause death     1.253 (0.661‐2.376)            0.490                                1.792 (0.849‐3.786)                     0.126   0.820 (0.329‐2.042)   0.669
  Cardiac death       1.295 (0.560‐2.997)            0.546                                1.688 (0.668‐4.269)                     0.269   0.816 (0.225‐2.967)   0.758
  *\<75 years old*                                                                                                                                              
  Primary end point                                                                                                                                             
  All‐cause death     0.673 (0.236‐1.923)            0.460                                0.958 (0.336‐2.732)                     0.937   0 (0)                 0.973
  Cardiac death       0.923 (0.215‐3.965)            0.914                                1.179 (0.268‐5.184)                     0.827   0 (0)                 0.993

Adjusted by age, sex, hypertension, dyslipidemia, diabetic mellitus, current smoker, renal dysfunction.

John Wiley & Sons, Ltd

###### 

Independent predictors of all‐cause death during follow‐up period

  Candidates variable                   Hazard ratio(95% CI)   *P*
  ------------------------------------- ---------------------- -------
  Presence of atrial fibrillation       1.048 (0.521‐2.108)    0.896
  Age                                   1.013 (0.981‐1.045)    0.442
  BMI                                   0.942 (0.861‐1.032)    0.200
  Dyslipidemia                          0.558 (0.304‐1.023)    0.059
  Diabetes mellitus                     1.506 (0.823‐2.755)    0.184
  Renal dysfunction                     1.971 (1.032‐3.761)    0.040
  Current smoker                        0.682(0.340‐1.372)     0.283
  Previous cerebral infarction or TIA   1.225 (0.558‐2.691)    0.612
  Previous peripheral artery disease    2.888 (1.019‐8.188)    0.046
  Killip\'s classification ≥2           2.429 (1.246‐4.736)    0.009
  Left ventricular ejection fraction    0.965 (0.936‐0.995)    0.024
  Left main trunk lesion ≥50%           1.136 (0.494‐2.613)    0.764
  Emergency PCI                         0.589 (0.292‐1.187)    0.139
  CABG                                  1.526 (0.485‐4.798)    0.470

BMI, body mass index; TIA, transient ischemic attack; PCI, Percutaneous coronary interventions; CABG, coronary artery bypass grafting.

John Wiley & Sons, Ltd

4. DISCUSSION {#joa312154-sec-0011}
=============

4.1. Comparison between the non‐AF and all‐AF groups {#joa312154-sec-0012}
----------------------------------------------------

In our study, incidence of all‐cause death was significantly higher in the all‐AF group than in the non‐AF group by Kaplan‐Meier analysis. However, there was no significant difference between the all‐AF and non‐AF groups by Cox proportional hazards regression analysis. In multivariate logistic regression analysis, AF was not an independent predictor of all‐cause death. Renal dysfunction, history of PAD, Killip classification ≥2, and LVEF remained independent predictors of all‐cause death. In the past, studies evaluating predictors of all‐cause death reported that lower LVEF or Killip classification, or both, was included in the independent predictor of all‐cause death.[3](#joa312154-bib-0003){ref-type="ref"}, [14](#joa312154-bib-0014){ref-type="ref"}, [22](#joa312154-bib-0022){ref-type="ref"}, [26](#joa312154-bib-0026){ref-type="ref"}, [27](#joa312154-bib-0027){ref-type="ref"} Some reports showed that renal dysfunction was the independent predictor of all‐cause death.[14](#joa312154-bib-0014){ref-type="ref"}, [27](#joa312154-bib-0027){ref-type="ref"} Renal dysfunction, history of PAD, and Killip classification ≥2 were significantly more prevalent in the all‐AF group than in the non‐AF group. LVEF tended to be lower in the all‐AF group than in the non‐AF group. We considered that, in this study, the presence of AF was not an independent predictor for all‐cause death, but prevalence of independent predictors was significantly higher in the all‐AF group. Therefore, incidence of all‐cause death was higher in the all‐AF group than in the non‐AF group. Previous reports demonstrated that prevalence of chronic kidney disease in patients with AF was significantly higher than in the corresponding non‐AF group.[31](#joa312154-bib-0031){ref-type="ref"} This study indicated that advanced age, congestive heart failure, and cardiovascular disease were independent predictors of complications due to AF.

In this study, patients with AF were older and the prevalence of Killip classification ≥2 and renal dysfunction were significantly higher than in patients without AF as previously reported[3](#joa312154-bib-0003){ref-type="ref"}, [15](#joa312154-bib-0015){ref-type="ref"}, [22](#joa312154-bib-0022){ref-type="ref"}, [26](#joa312154-bib-0026){ref-type="ref"} (Table [7](#joa312154-tbl-0007){ref-type="table"}). It was notable that these reports found all‐cause mortality to be higher in patients with AF than in those without.

###### 

Studies on ACS with AF

  Author                                                     Publication date   Number of patients   Follow‐up duration   Sub group (mortality %)                                                                                                                 Significant difference in prognosis
  ---------------------------------------------------------- ------------------ -------------------- -------------------- --------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------
  Comparison of 2 groups                                                                                                                                                                                                                                          
  Crenshaw et al[1](#joa312154-bib-0001){ref-type="ref"}     1997               40 891               1 y                  Non‐AF (8.4)/AF (21.5)                                                                                                                  \+
  Eldar et al[18](#joa312154-bib-0018){ref-type="ref"}       1998               2866                 1 y                  Non‐AF (15.4)/pAF (38.4)                                                                                                                \+
  Pedersen et al[3](#joa312154-bib-0003){ref-type="ref"}     1999               6676                 5 y                  Non‐AF (34)/AF (56)                                                                                                                     \+
  Rathore et al[19](#joa312154-bib-0019){ref-type="ref"}     2000               106 780              1 y                  Non‐AF (32.7)/AF (48.3)                                                                                                                 \+
  Wong et al[20](#joa312154-bib-0020){ref-type="ref"}        2000               13 858               1 y                  Non‐AF (NR)/new AF (NR)                                                                                                                 \+
  Goldberg et al[21](#joa312154-bib-0021){ref-type="ref"}    2002               2596                 5 y                  Non‐AF (NR)/new AF (NR)                                                                                                                 \+
  Kinjo et al[4](#joa312154-bib-0004){ref-type="ref"}        2003               2475                 1 y                  Non‐AF (7.9)/AF (18.9)                                                                                                                  \+
  Siu et al[6](#joa312154-bib-0006){ref-type="ref"}          2007               431                  1 y                  Non‐AF (5.6)/new AF (6.8)                                                                                                               ‐
  Lopes et al[7](#joa312154-bib-0007){ref-type="ref"}        2008               120 566              1 y                  Non‐AF (3.3)/AF (10.0)                                                                                                                  \+
  Saczynski et al[9](#joa312154-bib-0009){ref-type="ref"}    2009               7513                 5 y                  Non‐AF (NR)/AF (NR)                                                                                                                     \+
  Lin et al[22](#joa312154-bib-0022){ref-type="ref"}         2011               783                  30 d                 Non‐AF (4.7)/AF (12.9)                                                                                                                  \+
  Beukema et al[24](#joa312154-bib-0024){ref-type="ref"}     2012               1623, 1728           1.3 y                Non‐AF (5.0)/AF before PCI (21.0), Non‐AF (4.7)/AF after PCI (23.0)                                                                     \+
  Galvao et al[26](#joa312154-bib-0026){ref-type="ref"}      2014               902                  0.5 y                Non‐AF (5.9)/new AF (13.4)                                                                                                              \+
  Rene et al[27](#joa312154-bib-0027){ref-type="ref"}        2014               3602                 3 y                  Non‐AF (6.3)/new AF (11.9)                                                                                                              \+
  Comparison of 3 or more groups                                                                                                                                                                                                                                  
  Sakata et al[2](#joa312154-bib-0002){ref-type="ref"}       1997               1039                 8 y                  Non‐AF (NR)/pre‐AF (NR)/new AF (NR)[a](#joa312154-note-0012){ref-type="fn"}                                                             \+
  Letho et al[5](#joa312154-bib-0005){ref-type="ref"}        2005               5477                 3 y                  Non‐AF (14.9)/pre‐AF (33.0)[a](#joa312154-note-0012){ref-type="fn"}/new AF (18.0)[a](#joa312154-note-0012){ref-type="fn"}               \+
  Lau et al[8](#joa312154-bib-0008){ref-type="ref"}          2009               3393                 1 y                  Non‐AF (NR)/pre‐AF (NR)[a](#joa312154-note-0012){ref-type="fn"}/new AF (NR)                                                             \+
  Jarbe et al[11](#joa312154-bib-0011){ref-type="ref"}       2011               3220                 30 d                 Non‐AF (NR)/pre‐AF (NR)[a](#joa312154-note-0012){ref-type="fn"}/new AF (NR)[a](#joa312154-note-0012){ref-type="fn"}                     \+
  Maagh et al[13](#joa312154-bib-0013){ref-type="ref"}       2011               375                  2 y                  Non‐AF (17.8)/cAF (45.5)[a](#joa312154-note-0012){ref-type="fn"}/new AF (25.0)                                                          \+
  Poci et al[25](#joa312154-bib-0025){ref-type="ref"}        2012               2335                 10 y                 Non‐AF (36.3)/pre‐pAF (69.0)/pre‐cAF (78.0)/new AF on admission (68.0)/new AF during admission (53.2)                                   − (among the subgroup with AF)
  Podolecki et al[14](#joa312154-bib-0014){ref-type="ref"}   2012               2980                 3.5 y                Non‐AF (17.0)/pre‐pAF (21.7)/new AF (35.8)[a](#joa312154-note-0012){ref-type="fn"}/cAF (54.3)[a](#joa312154-note-0012){ref-type="fn"}   \+
  Gaca et al[15](#joa312154-bib-0015){ref-type="ref"}        2015               1373                 0.5 y                Non‐AF (3.6)/pre‐AF (10.6)[a](#joa312154-note-0012){ref-type="fn"}/new‐AF (6.3)                                                         \+
  Systematic review or meta‐analysis                                                                                                                                                                                                                              
  Schimitt et al[10](#joa312154-bib-0010){ref-type="ref"}    2009               NR                                        NR                                                                                                                                      NR
  Jarbe et al[12](#joa312154-bib-0012){ref-type="ref"}       2011               278 854                                   Non‐AF (NR)/pre‐AF (NR)[a](#joa312154-note-0012){ref-type="fn"}/new AF (NR)[a](#joa312154-note-0012){ref-type="fn"}                     \+
  Angeil et al[23](#joa312154-bib-0023){ref-type="ref"}      2012               235 511                                   Non‐AF (7.5)/pre‐AF (8.3), Non‐AF (10.5)/new AF (20.8)[a](#joa312154-note-0012){ref-type="fn"}                                          \+

Pre‐AF, pre‐existing AF; new AF, new‐onset AF; pAF, paroxysmal AF; cAF, chronic AF; NR, not reported; Y, year(s); D, day(s).

The group that had a significant difference compared with the non‐AF group in long‐term prognosis.
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4.2. Comparison among the non‐AF group, the new‐onset AF group, and the pre‐existing AF group {#joa312154-sec-0013}
---------------------------------------------------------------------------------------------

We analyzed the relevance of time of onset of AF. Previous reports concluded that patients with new‐onset AF had a worse prognosis[2](#joa312154-bib-0002){ref-type="ref"}, [5](#joa312154-bib-0005){ref-type="ref"}, [8](#joa312154-bib-0008){ref-type="ref"}, [12](#joa312154-bib-0012){ref-type="ref"}, [14](#joa312154-bib-0014){ref-type="ref"}, [15](#joa312154-bib-0015){ref-type="ref"}, [20](#joa312154-bib-0020){ref-type="ref"}, [21](#joa312154-bib-0021){ref-type="ref"}, [23](#joa312154-bib-0023){ref-type="ref"}, [26](#joa312154-bib-0026){ref-type="ref"}, [27](#joa312154-bib-0027){ref-type="ref"} (Table [7](#joa312154-tbl-0007){ref-type="table"}). In this study, Kaplan‐Meier analysis demonstrated significant differences for all‐cause death in the three groups; in particular, the new‐onset AF group showed the poorest outcome. However, in the Cox proportional hazards regression analysis, adjusted for several factors, there were no significant differences in all‐cause death among the three groups. Most of the past studies that reported on three or more groups were studied with only Kaplan‐Meier analysis[2](#joa312154-bib-0002){ref-type="ref"}, [13](#joa312154-bib-0013){ref-type="ref"}, [14](#joa312154-bib-0014){ref-type="ref"}, [15](#joa312154-bib-0015){ref-type="ref"}, [25](#joa312154-bib-0025){ref-type="ref"} (Table [7](#joa312154-tbl-0007){ref-type="table"}). Only three reports were studied with Cox proportional hazards regression analysis[5](#joa312154-bib-0005){ref-type="ref"}, [8](#joa312154-bib-0008){ref-type="ref"}, [11](#joa312154-bib-0011){ref-type="ref"} (Table [7](#joa312154-tbl-0007){ref-type="table"}). Lau et al[8](#joa312154-bib-0008){ref-type="ref"} reported that incidence of all‐cause death was significantly higher in the new‐onset AF group than in the non‐AF group by Kaplan‐Meier analysis. However, on the Cox proportional hazards regression analysis, adjusted for several factors, there were no significant differences in all‐cause death between the two groups. Incidence of all‐cause death in the pre‐existing group was still significantly higher than in the non‐AF group after adjustment. In this study, Killip classification and LVEF were significant predictors of all‐cause death, and prevalence of Killip classification ≥2 was significantly higher and LVEF was lowest in the new‐onset AF group. Furthermore, on the Cox proportional hazards regression analysis, prevalence of CHF requiring hospitalization was significantly higher in the new‐onset AF group than in the non‐AF group. Therefore, we considered that a high prevalence of Killip classification ≥2 and lower LVEF were directly associated with long‐term mortality and CHF requiring hospitalization in the new‐onset AF group. Strict management during the follow‐up period is needed for the ACS patients complicating with new‐onset AF.

In this study, we evaluated CHADS~2~ scores. Among previous studies, none reported CHADS~2~ score for ACS research‐related AF. CHADS~2~ score and distribution of CHADS~2~ scores were significantly higher in the pre‐existing AF group than in the new‐onset AF group. The incidence of the previous cerebral infarction or TIA was significantly higher in the pre‐existing AF group than in the new‐onset AF group. The results may be due to the higher CHADS2 score in the pre‐existing AF group.

4.3. Study limitations {#joa312154-sec-0014}
----------------------

There were several limitations with this study. First, the number of patients was relatively small, and the study was retrospective in nature. Second, although our definition of AF included persistent and paroxysmal AF, our study did not illustrate these differences. AF type may determine mortality. Finally, the precise period of antiplatelet and anticoagulant drug treatment was unclear because drug prescription during follow‐up was carried out at private outpatient clinics in almost all the cases. In this study, the influence of medication was unclear.

5. CONCLUSION {#joa312154-sec-0015}
=============

In our study, AF was not an independent predictor of all‐cause death in ACS patients, but renal dysfunction, history of PAD, and Killip classification ≥2 were independent predictors. Prevalence of these independent predictors was significantly higher in ACS patients complicated with AF. In particular, ACS patients complicating with new‐onset AF had a higher prevalence of Killip classification ≥2, lower LVEF, and a significant risk for CHF requiring hospitalization during the follow‐up. Therefore, ACS patients with new‐onset AF may have a worse prognosis.
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